Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

The wisdom of crowds and the repurposing of artesunate as an anticancer drug.

Augustin, Y; Krishna, S; Kumar, D; Pantziarka, P (2015) The wisdom of crowds and the repurposing of artesunate as an anticancer drug. ecancermedicalscience, 9. ed50. ISSN 1754-6605
SGUL Authors: Krishna, Sanjeev

PDF Published Version
Available under License Creative Commons Attribution.

Download (334kB) | Preview


Artesunate, a semi-synthetic and water-soluble artemisinin-derivative used as an anti-malarial agent, has attracted the attention of cancer researchers due to a broad range of anti-cancer activity including anti-angiogenic, immunomodulatory and treatment-sensitisation effects. In addition to pre-clinical evidence in a range of cancers, a recently completed randomised blinded trial in colorectal cancer has provided a positive signal for further clinical investigation. Used perioperatively artesunate appears to reduce the rate of disease recurrence - and the Neo-Art trial, a larger Phase II RCT, is seeking to confirm this positive effect. However, artesunate is a generic medication, and as with other trials of repurposed drugs, the Neo-Art trial does not have commercial sponsorship. In an innovative move, the trial is seeking funds directly from members of the public via a crowd-funding strategy that may have resonance beyond this single trial.

Item Type: Article
Additional Information: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: ecancermedicalscience
ISSN: 1754-6605
Language: eng
13 October 2015Published
Publisher License: Creative Commons: Attribution 3.0
PubMed ID: 26557887
Go to PubMed abstract
Publisher's version:

Actions (login required)

Edit Item Edit Item